ACM
BLUE

Atika Capital Management’s bluebird bio BLUE Stock Holding History

Atika Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-556
Closed -$1.21M – 64
2015
Q2 		$1.21M Buy
+556
New +$1.13M 0.55% 57

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Atika Capital Management's BLUE Position: Q4 2018 in Review

Atika Capital Management sold out of bluebird bio (BLUE) in Q4 2018, closing a stake of 1,397 shares — an estimated $2.64M sold.

Atika Capital Management first reported a position in BLUE in Q4 2014 and held it in 10 quarters. The position peaked at $4.72M in Q4 2017. 251 funds tracked by Wall St. Rank hold BLUE as of Q4 2018.

  • Atika Capital Management reported no remaining bluebird bio position as of Q4 2018 after selling out during the quarter.
  • Atika Capital Management sold 1,397 bluebird bio shares in Q4 2018, an estimated $2.64M.
  • Atika Capital Management first reported a position in bluebird bio in Q4 2014 and held it in 10 quarters.
  • Atika Capital Management's bluebird bio position peaked at $4.72M in Q4 2017.
  • 251 funds tracked by Wall St. Rank held bluebird bio as of Q4 2018.

Based on Atika Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.